Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
复制标题
DOI：
10.1517/14712598.4.7.1159
复制
发表时间：
2004-07-01
影响因子：
4.6
通讯作者：
Berek, JS
中科院分区：
文献类型：
--
作者：
Berek, JS
恶性肿瘤的分子和细胞生物学和肿瘤免疫学的最新进展刺激了免疫疗法作为癌症辅助治疗的应用取得了重大进展。 Oregovomab (OvaRex(R) AltaRex) 是一种鼠单克隆抗体，对卵巢癌相关抗原 CA125 具有高亲和力。低剂量抗体的输注会导致循环免疫复合物的形成，从而触发针对 CA125 和卵巢癌的细胞免疫反应。 Oregovomab 在初始化疗后和复发性疾病中具有活性，目前正在进行 III 期试验，以确定其延长晚期卵巢癌患者复发时间的功效以及一线治疗的良好结果。关于抗原加工和联合化疗免疫疗法的其他研究正在进行中。该治疗有望成为卵巢癌标准治疗的潜在新疗法。
Recent advances in the molecular and cellular biology of malignancy and tumour immunology have stimulated significant progress in the application of immunotherapies as adjuvant treatments in cancer. Oregovomab (OvaRex(R) AltaRex) is a murine monoclonal antibody with high affinity to the ovarian cancer associated antigen CA125. Infusion of low-dose antibody results in formation of circulating immune complexes which can trigger a cellular immune response targeting CA125 and the ovarian cancer. Oregovomab has activity following initial chemotherapy and in recurrent disease settings and is in Phase III trials to establish its efficacy to prolong time to relapse in patients with advanced ovarian cancer and favourable outcomes to their front-line treatment. Additional studies of antigen processing and combination chemo-immunotherapy are ongoing. The treatment shows promise as a potential new addition to the standard care of ovarian cancer.